{
    "organizations": [],
    "uuid": "b4f057203b7195fd09b82ab6b039e28928b6aa22",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-botanix-pharmaceuticals-updates-on/brief-botanix-pharmaceuticals-updates-on-phase-1b-study-of-btx-1503-idUSFWN1PL1B6",
    "ord_in_thread": 0,
    "title": "BRIEF-Botanix Pharmaceuticals Updates On Phase 1b Study Of BTX 1503",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Botanix Pharmaceuticals Ltd:\n* ‍ PHASE 1B STUDY OF BTX 1503 IN PATIENTS WITH MODERATE TO SEVERE ACNE MET ALL DESIGNATED ENDPOINTS ​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T07:11:00.000+02:00",
    "crawled": "2018-01-29T21:59:19.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "botanix",
        "pharmaceutical",
        "ltd",
        "phase",
        "1b",
        "study",
        "btx",
        "patient",
        "moderate",
        "severe",
        "acne",
        "met",
        "designated",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}